Betting on Bubble Technology: From Alzheimer’s Treatment to Enhanced Cancer Drug DeliveryUltrasound-based therapies hold immense potential for improving patient care and advancing precision medicine — but it‘s the bubble, not…Feb 29, 2024Feb 29, 2024
Unlocking the Power of Precision: Antibody-Drug Conjugates in OncologyBy Clayton Larsen — President & CEO, Vesselon Inc.Feb 6, 2024Feb 6, 2024
Overview: Vesselon’s Transformative Coformulation MethodBy Clayton Larsen — President & CEO, Vesselon Inc.Jan 15, 2024Jan 15, 2024
Emerging Dynamics in the Biopharmaceutical Industry: An Analysis of Mergers and Acquisitions TrendsBy Vesselon, Inc.Dec 31, 2023Dec 31, 2023
How Vesselon Can Improve the Entire Class of RadiopharmaceuticalsBy Clayton Larsen — President & CEO, Vesselon, Inc.Nov 1, 2023Nov 1, 2023
How Vesselon Can Improve the Entire Class of Antibody-Drug ConjugatesBy Clayton Larsen — President & CEO, Vesselon, Inc.Oct 5, 2023Oct 5, 2023
Webinar: How Biophysics Can Change the Receive Characteristics of Characteristics of TumorsIt is believed that interstitial fluid pressure and solid stress are major obstacles preventing efficient delivery of macromolecules into…Aug 24, 2023Aug 24, 2023
Harnessing Sonoporation and Lipid Encapsulation: Vesselon’s Breakthrough in Drug DeliveryBy Clayton Larsen — President & CEO, Vesselon, Inc.Jul 5, 2023Jul 5, 2023
